ACEA Release: Live Cell Analysis Using xCELLigence Instruments: Searchable Library of Over 1,400 Publications Now Online

Dec. 28, 2017 10:00 UTC

ACEA Biosciences makes available an exhaustive library of xCELLigence papers spanning 15 years and applications ranging from immune cell killing and cell invasion/migration to viral cytopathic effect and cardiotoxicity screening



SAN DIEGO--(BUSINESS WIRE)-- In 2002 ACEA Biosciences, Inc. pioneered real-time cellular impedance as a tool for dynamically tracking cell number, cell size, cell-substrate attachment strength, and cell invasion/migration. Now encompassing a line of seven different xCELLigence Real-Time Cell Analysis (RTCA) instruments, this label-free and noninvasive approach to cell-based assays makes use of gold biosensors to continuously track cell health and behavior in diverse contexts. xCELLigence combines high throughput capability with rapid data acquisition, reading 96 well plates in less than 15 seconds. Owing to its high reproducibility and dramatically simplified workflow relative to traditional endpoint experiments, cellular impedance has rapidly become the go-to assay for dozens of different applications in fields spanning from cancer and infectious diseases to regenerative medicine and vaccine development. More than 2,000 xCELLigence RTCA instruments are currently being used in academic, government, industrial, and CRO laboratories worldwide, leading to >1,400 peer-reviewed research articles.

As a tool for viewing these real world examples of xCELLigence RTCA’s utility for specific applications, today ACEA launched a comprehensive and searchable online library. “By compiling all these publications in a single location, our hope is to make this information, including protocols, more immediately accessible for prospective and existing users of the xCELLigence RTCA technology,” stated Dr. Jeff Xue, ACEA’s Director of Global Marketing & Corporate Development. To view the new library, click here.

About ACEA Biosciences

Founded in 2002, ACEA Biosciences is a pioneer in the development and commercialization of high performance, cutting edge cell analysis platforms for life science research. ACEA’s xCELLigence® impedance-based, label-free, real-time cell analysis instruments and NovoCyte® flow cytometer are used in pre-clinical drug discovery and development, toxicology, safety pharmacology, and basic academic research.

For more information visit:



ACEA Biosciences, Inc.
Dr. Jeff Xue
1-858-724-0928, x3075



Source: ACEA Biosciences, Inc.

Back to news